Oseltamivir has been used for treatment of infl uenza A and B infections, but recent reports documented that it was less active against the latter. We compared the effectiveness of oseltamivir in children between laboratory confi rmed infl uenza A and B over 4 infl uenza seasons from 2001 to 2005 in a pediatric clinic in Japan. Among 1,848 patients screened, 299 infl uenza A and 209 infl uenza B patients were administered oseltamivir (treated groups), and 28 infl uenza A and 66 infl uenza B patients were assigned as non-treated groups. The duration of fever, defi ned as period when patients had the maximum temperature higher than 37.5°C in three-time measurements in a day after the clinic visit, was evaluated among the four groups. In uni-variate analysis, the duration of fever was shorter for treated group than non-treated for infl uenza A (1.8 ± 0.9 days vs 2.6 ± 1.3 days, p < 0.01), but it was not signifi cant for infl uenza B (2.4 ± 1.3 days vs 2.8 ± 1.2 days, p = 0.9). The fever duration was longer in treated infl uenza B than A patients ( p < 0.01). Multi-variate analysis indicated younger age ( < 6 years old) and higher body temperature at the clinic visit prolonged the duration of fever. Adjusted average duration of fever indicated that oseltamivir was effective for both types, but more effective on infl uenza A, and the benefi t increased for younger children. Our data provide evidence that oseltamivir is benefi cial for infl uenza infections, but the effectiveness is differed by type and age. infl uenza; anti-viral drugs; oseltamivir; children; effectiveness.
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Infl uenza outbreaks occur annually across the world, causing excess morbidity and mortality (Simonsen et al. 2000; Nicholson et al. 2003 ; Centers for Disease Control and Prevention 2006) . For infl uenza treatment, there are two types of anti-infl uenza drug: amantadine and neuraminidase inhibitors (oseltamivir and zanamivir) (Monto 2003; Oxford et al. 2003; Moscona 2005; Oxford 2005; Jefferson et al. 2006) . Amantadine is effective for treatment of infl uenza infl uenza A or B infections.
Patients were assigned to infl uenza treatment or non treatment groups, depending whether or not they want to receive antiviral drug medication according to the rapid test results. For patients with infl uenza A, the decision of whether to receive antivirals (oseltamivir or amantadine) or not was left to patients or their family. For infl uenza B, patients could choose either oseltamivir or no antiviral therapy. The two drugs were administered twice daily (oseltamivir, 150 mg per day for children 37.5 kg in weight; or 4 mg/kg for children with < 37.5 kg: amantadine, 1.5-2.5 mg/kg). Both drugs were prescribed for 5 days. For some patients, administration of drugs was discontinued if symptoms were alleviated within 5 days. Single use of antipyretics was allowed when a child had a fever more than 38.5°C.
Written informed consent was acquired from parents of patients to obtain clinical information and specimens for virological investigations upon enrollment to the study. Age, sex, body weight, vaccination status, use of antipyretics, type of drug, the time from the onset of fever to the administration of anti-infl uenza drug, body temperatures, and the results of rapid antigen test kits were recorded for all patients by the clinician at the time of report to the clinic. The parents were given a diary card to record body temperatures 3 times daily (at 9 : 00, 12 : 00 and 20 : 00 o'clock) and any symptoms such as cough, rhinorrhea, sore throat, fatigue, appetite loss, myalgia, vomiting, or diarrhea, occurring up to 5 days after the therapy started. Parents were requested to return the card by visiting or mailing to the clinic after completion of the course. Time until treatment was defi ned as days from fever onset until the clinic visit.
Nasopharyngeal swabs or aspirates were collected from the patients, placed in viral transport medium, and then transferred to the Department of Public Health, Niigata University Graduate School of Medical and Dental Sciences. The samples were stored at 4°C for a few days until viral culture, and aliquots were kept at −80°C. For virus isolation, supernatants of specimens were inoculated into Madin-Darby canine kidney cells. Types and subtypes were determined by hemagglutination inhibition tests with type-specifi c antisera (Masuda et al. 2000) . Detection of the infl uenza genome was performed by reverse transcription-polymerase chain reaction (RT-PCR) (Saito et al. 2002) . Briefl y, viral RNA was extracted from nasopharyngeal aspirate specimens and reverse transcription reactions were performed for complementary DNA synthesis as described previously A virus infections while neuraminidase inhibitors are for both infl uenza A and B (Treanor et al. 2000) . Early treatment reduces the severity and duration of infl uenza illness and associated complications (Nicholson et al. 2000; Aoki et al. 2003; Kawai et al. 2005) .
The neuraminidase inhibitors, zanamivir and oseltamivir, interfere with the release of progeny infl uenza viruses from infected host cells and spread to neighboring cells in the respiratory tract. Clinical effi cacy of oseltamivir has been established as treatment for infl uenza in adults (Hayden et al. 1999; Nicholson et al. 2000; Treanor et al. 2000) and children (Whitley et al. 2001) . The neuraminidase inhibitors were tested to be less active against infl uenza B than A viruses in vitro studies (Boivin and Goyette 2002; Aoki et al. 2003; Mungall et al. 2004) . Moreover, increasing evidence suggests that oseltamivir is less effective against infl uenza B than infl uenza A infections (Kawai et al. 2006; Sugaya et al. 2007 ). The present study was conducted to evaluate the effi cacy of oseltamivir treatment among children with infl uenza A and B virus infections during four successive winters in Japan using uni-variate and multi-variate analysis adjusted for various factors that affect the course of illness.
MATERIALS AND METHODS

Study population and laboratory methods
This study was conducted during 4 infl uenza seasons from November 2001 to May 2005 at a private pediatric outpatient clinic located at the city center in Niigata City, Japan with a total population of approximately 500,000. This clinic had no bed facility, and approximately 2,300 outpatients visited per month.
Infl uenza-like illness was defi ned on the basis of a sudden fever ( 37.5°C) and any acute respiratory symptoms and signs, such as, cough, rhinorrhea, sneezing, wheezing, sore throat, headache, nausea, or malaise. Nasopharyngeal swabs or aspirates were examined with rapid antigen test kits for diagnosis of infl uenza A or B prior to antiviral drug treatment (oseltamivir or amantadine) at the initial offi ce visits. Infl uenza rapid test kits, such as QuickVue Rapid SP infl u (DS Pharma Biomedical Co., Ltd., Osaka), Espline Infl uenza A&B-N (Fujirebio Inc., Tokyo), and Quick S-Infl u A/B "SEIKEN" (Denkaseiken Co., Ltd., Tokyo) were used to screen (Masuda et al. 2000) . First and nested PCR was performed to detect generic infl uenza A, using M2 gene primers (Masuda et al. 2000) . Infl uenza B was detected in separate PCR runs using infl uenza B hemagglutinin gene primers (Shimizu et al. 1997) . In this study, we defi ned "infl uenza infections" as PCR or virus isolation positive regardless of rapid test results (Fig. 1 ). This study was approved by the Medical Faculty Ethics Committee of the Niigata University, Graduate School of Medical and Dental Sciences.
Effectiveness of oseltamivir
Infl uenza-related fever was defi ned as body temperature of more than 37.5°C (99.5 F) using the highest body temperature among three different time measurements in a day. The effectiveness was evaluated by the fever duration more than 37.5°C after the fi rst visit to clinic.
Statistical analysis
Statistical comparisons for baseline characteristics among the 4 groups by type of infl uenza and treatment were made by chi-square test to evaluate the proportions in multiple groups, and one-way analysis of variance to compare the mean values. Sheffe's test was used as univariate analysis to compare average values for the duration of fever among the four clinical groups. General linear model was employed as multi-variate analysis to assess independent variable which infl uenced the duration of fever and to estimate the adjusted average days for duration of fever by type and treatment. All statistical analyses were performed with SPSS 11.0J (SPSS Japan Inc., Tokyo). P < 0.05 was considered statistically signifi cant.
RESULTS
Patient characteristics
A total of 1,848 individuals with infl uenzalike illness were screened during the four successive seasons for the study (Fig. 1 ). Among these, 1,130 (61.1%) patients were positive for infl uenza with virus isolation or PCR, but nearly half of patients were excluded due to the reasons listed in the Fig. 1 . As a result, a total of 602 patients (5 of infl uenza A/H1N1, 257 of A/H3N2, and 257 of B were identifi ed by virus isolation, and 65 of infl uenza A and 18 of infl uenza B by PCR) were enrolled in the study. They were divided into four groups by type of infl uenza and oseltamivir treatment status: 299 infl uenza A patients received oseltamivir treatment (treated infl uenza A), and 28 without treatment (non-treated infl uenza A), and 209 infl uenza B patients with treatment (treated infl uenza B) and 66 without treatment (non-treated infl uenza B), respectively ( Table 1) . The mean age and body weights, vaccination status, and the time until treatment did not differ signifi cantly among the four groups. Body temperature at the time of clinic visit was higher in treated infl uenza A patients than treated infl uenza B, and younger patients (< 6 years old) had higher temperature than older ones ( 6 years old) in all groups.
Effectiveness of oseltamivir treatment for infl uenza A and B
The duration of fever was shorter in the treatment group as compared to the non treatment in infl uenza A (1.8 ± 0.9 days vs 2.6 ± 1.3 days; p < 0.01), but infl uenza B did not have statistical signifi cance (2.4 ± 1.3 days vs 2.8 ± 1.2 days; p = 0.09) ( Table 2 ). The fever duration was longer for infl uenza B treatment group (2.4 ± 1.3 days) than infl uenza A treatment group (1.8 ± 0.9 days; p < 0.01). In all four groups, duration of fever was signifi cantly longer in younger (< 6 years old) than older children ( 6 years old) ( Table 2) . For younger group, the duration of fever was statistically shorter in treatment groups than non-treatment for both infl uenza A (3.1 ± 1.3 days vs 1.9 ± 1.0 days, p < 0.01, balance between the two = 1.2 days), and infl uenza B (3.2 ± 1.1 days vs 2.7 ± 1.3 days, p < 0.05, balance between the two = 0.5 days), but not in older children for both infl uenza 4.9 ± 4.0 5.8 ± 3.6 5.7 ± 2.3 6.4 ± 2.7 0.044 Body temperature at the clinic visit (°C) 39.1 ± 0.6 39.2 ± 0.6 38.9 ± 0.6 39.0 ± 0.6 0.000 Body weight (kg) 17.8 ± 10.0 22.5 ± 11.6 20.2 ± 6. Numbers are mean ± S.D. or n (%). a Chi-square test were employed for multiple rows and column contingency table, and one-way analysis of variance was used to compare means in multiple groups.
b Time until treatment, the time from the onset of fever to the clinic visit. A (2.0 ± 1.2 days vs 1.6 ± 0.7 days, n.s., balance between the two = 0.4 days), and infl uenza B (2.5 ± 1.1 days vs 2.2 ± 1.3 days, n.s., balance between the two = 0.3 days). However, the fever duration was consistently shorter in treated infl uenza A than treated B for the two age categories. We examined independent variable factors infl uencing the duration of fever using general linear model as multi-variate analysis (Table 3) . Of variables analyzed, treatment of oseltamivir was a factor that attributed to the reduction of the fever duration by 1.32 days, whereas infl uenza B virus infection did not affect the illness duration signifi cantly. Patients who were less than 6 years old exhibited the prolonged duration of fever by 0.71 days, and as well as one degree higher body temperature at the clinic visit by 0.55 days.
Average duration of fever was estimated in the four groups with adjustment for age, gender, body weight, infl uenza season, vaccination status, time until treatment, and body temperature at the clinic visit. The treatment groups had signifi cantly shorter duration of fever than non-treatment groups for both infl uenza A (2.0 days vs 3.1 days, p < 0.01) and infl uenza B (2.8 days vs 3.2 days, p < 0.05) ( Table 2 ). The duration was longer in treated infl uenza B than treated infl uenza A ( p < 0.01), as in the uni-variate analysis. After stratification by age groups (< 6 years old, or 6 years old), average duration was consistently longer for all four groups in younger children than older ones (Table 2 ). In younger children (< 6 years old), the fever duration was signifi cantly shorter in treated groups than non-treated for infl uenza A (3.6 days vs 2.1 days, p < 0.01, balance between the two = 1.5 days), but not for infl uenza B (3.5 days vs 2.9 days, p = 0.74, balance between the two = 0.6 days). In older children ( 6 years old), statistical signifi cance was not demonstrated for both infl uenza A (2.5 days vs 1.8 days, n.s., balance between the two = 0.7 days) and B (2.9 days vs 2.6 days, n.s., balance between the two = 0.3 days). For the two age groups, treated infl uenza B had consistently longer fever duration than infl uenza A counterparts.
DISCUSSION
The clinical results in this paper provided evidence that oseltamivir was effective in reducing the duration of fever for both infl uenza A and B infections, but was less effective for infl uenza B infections rather than infl uenza A. Even after adjustment with various underlying factors, or categorization by age groups, the duration of fever in the treatment groups was consistently longer for infl uenza B than infl uenza A.
Oseltamivir has been thought to be equally effective against infl uenza A and B infections (Hayden et al. 1999; Whitley et al. 2001 ), but growing clinical evidence suggests oseltamivir is less effective against infl uenza B than infl uenza A. Our results were basically similar to the previous fi ndings from Japan (Kawai et al. 2006; Sugaya et al. 2007 ). However, we emphasize that we carried out the study in multiple years, and enrolled suffi cient number of non-treated groups for both infl uenza A and B in order to evaluate the effectiveness of the drug, in comparison with the pre- vious studies implemented in a single year, and included relatively limited number of non-treated patients (Kawai et al. 2006; Sugaya et al. 2007 ). In addition, multi-variate analysis was employed to estimate the most infl uencing factors for the duration of fever, on the top of uni-variate analysis, which might be affected by confounding factors.
In our study, adjusted average duration of fever showed that treated infl uenza B had longer clinical course than treated infl uenza A. In vitro data suggested that the IC 50 of infl uenza B virus to oseltamivir was higher than infl uenza A/H3N2 and A/H1N1 (Gubareva et al. 2001; Boivin and Goyette 2002; Hurt et al. 2004; Sugaya et al. 2007 ). Also, longer virus shedding was observed with infl uenza B than infl uenza A after oseltamivir treatment (Kawai et al. 2007 ). These data suggested that infl uenza B was less susceptible to oseltamivir than infl uenza A in vitro and in vivo. However, increasing the dosage for infl uenza B may not be advisable, since it prompts the issues of increased adverse effects. Choosing zanamivir for infl uenza B treatment is one of options (Kawai et al. 2008 ), but age limitations to this inhaling drug ( 5 years old) makes it diffi cult to generalize in pediatric practices.
Fever duration was consistently longer in younger children than older ones regardless of treatment. It is generally accepted that younger children with few previous infl uenza infections possessed prolonged course of illness and higher virus titer, due to insuffi cient inhibition of viral replication and higher cytokine levels. (Kiso et al. 2004; Kawai et al. 2008 ). In our analysis, oseltamivir seemed to be more effective in younger children than older children. It is true that insufficient number in some groups for older children (especially non-treated groups) made the results diffi cult to interpret, but statistical signifi cance were more obvious in younger children than older ones. Also, the balance of fever duration between treated and non-treated was wider for younger children than older children for both infl uenza A and B. Despite the fact that the younger children had prolonged fever, the effect of treatment could be expected more in these groups. We need further investigations by enrolling larger number of children for confi rmation.
In our multi-variate analysis, time from the onset to the clinic did not affect the fever duration as an independent variable. This is contrary to Kawai et al., reporting an increased benefi t with early report to the clinic for the duration of fever (Kawai et al. 2008) . These contrasting results were derived from the different criteria for fever duration between the two studies.
Higher body temperature at the fi rst clinic visit was also a prolonging factor for fever duration as in the previous study (Kawai et al. 2008) , suggesting the infl uences of higher viral replication and increased cytokines levels (Kiso et al. 2004; Kawai et al. 2008 ).
In conclusion, our study demonstrated the clinical effectiveness of oseltamivir for both infl uenza A and B patients, compared to non-treated patients. However, illness was prolonged for infl uenza B infections than infl uenza A under the treatment of oseltamivir.
